BioMelbourne Network Progressing BioIndustry

22 July (Melb) - Plastics for Medical Applications
This seminar sponsored by Comtec IPE and Polymers International Australia will cover More

Victorian BioPortal

Looking for Something?

The Victorian BioPortal is the largest online search engine for biotechnology in Victorian with over 2,000 individual listings.

Start your search now

BioMelbourne Network

The Building Global Bridges program provides grants of between $100,000 & $500,000 to Victorian life science companies to develop partnerships with Massachusetts companies in late stage life sciences R&D projects. The program helps Victorian innovation to accelerate, access expertise, develop skills & better reach global markets and international investors. Applications close 17 September 2013.

Building Global Bridges

Phosphagenics' $19.3 million Capital Raising

11th July, 2014 - • Includes $3 million Share Purchase Plan• Upcoming opioid pain patch trials fully funded 11 July 2014, Melbourne:  Australian drug delivery company, Phosphagenics Limited (ASX:POH; OTCQX:PPGNY),has raised $19.3 million via a placement of $16.3 million to institutional and sophisticated investors in Europe, USA, Asia and Australia and $3 million from a share purchase plan (SP... read more…

Melbourne hosting the 20th International AIDS Conference (AIDS 2014)

9th July, 2014 - Participants from the biotechnology sector highlighted that Melbourne has the capability in this sector but it is challenging to promote it to potential clients who have not been to Melbourne and experienced the facilities. For international investors, seeing the facilities and the people who are part of a project is critical. Participants know that when investors visit Melbou... read more…

LBT INNOVATIONS PRESENTS RESULTS OF MOST EXTENSIVE STUDY OF LANDMARK APAS® TECHNOLOGY AT AUSTRALIAN CONFERENCE

7th July, 2014 - Australian  medical  technology  developer,  LBT  Innovations Limited  (ASX:  LBT),  yesterday presented the results of its most extensive study to date into the efficacy of its Automated Plate Assessment System (APAS®) – a breakthrough culture plate analysis system based on the company’s innovative intelligent image interpretation platform. The presentation by LBT’s Senior Mi... read more…

BioMelbourne Network Announces New CEO

4th July, 2014 - On behalf of the BioMelbourne Network board, I am delighted to announce the appointment of Dr Krystal Evans to the role of Chief Executive Officer. She will commence her full time duties in early August 2014 but will begin engagement with our members and secretariat during the month of July. Krystal is a well recognised advocate for science and technology in Australia, with a ... read more…

dorsaVi acquires Australian Workplace Compliance to drive OH&S market expansion

4th July, 2014 - Medical device company dorsaVi Limited (ASX: DVL) (“the Company”) has today announced the acquisition of Australian Workplace Compliance Pty Ltd to increase the Company’s service offering and client base in the occupational health and safety (OH&S) market. Australian Workplace Compliance was founded by Mark Heaysman and provides OH&S operational and procedural analysis, suppor... read more…

d3 Medicine LLC and Viroclinics Biosciences BV form Virology Drug Development Alliance

2nd July, 2014 - We are thrilled to announce today that we have formalised collaborations with Viroclinics Biosciences - a recognised global leader in diagnostic, preclinical and clinical operation services in the virology space. Please see the attached press release. Together we seek to provide biopharmaceutical customers with an integrated solution to accelerate the preclinical and clinical ... read more…

Australia Jumps to Fourth in Global Biotech Ranking

1st July, 2014 - Melbourne, Australia’s leading life sciences industry on display at 2014 BIO International Convention San Diego, CA - July 1, 2014 - More than 70 delegates from Melbourne, Australia attended the 2014 BIO International conference showcasing their strong life sciences cluster.  At this year’s convention, Scientific American Worldview announced its annual global rankings of the b... read more…

Dr John Dixon Hughes OAM Medal for Medical Research Innovation

26th June, 2014 - The National Foundation for Medical Research and Innovation (NFMRI) is pleased to offer the Dr John Dixon Hughes OAM Medal for Medical Research Innovation every two years to a researcher under the age of 45 for outstanding contribution towards the development and advancement of a biomedical innovation related to the nature, prevention, diagnosis, treatment and incidence of dis... read more…

Bionomics and Merck Enter New Research Collaboration

24th June - Agreement to fund development of compounds for cognitive impairment associated with Alzheimer’s disease and other conditions of the central nervous system.Bionomics Limited (ASX:BNO, ADR:BMICY) announces that it has entered into an exclusive Research Collaboration and License Agreement with Merck, known as MSD outside the United States and Canada, for its BNC375 research program tar... read more…

Wild Success In Time Of Challenge

23rd June - Wild Child cosmeceuticals is set to float on the Australian stock exchange, in the latest bid for a global reach by the WA company that started on a kitchen table. Founder Leanne Preston said a new state-of-the-art factory in Malaga - a milestone move that bucks the trend to go offshore - as well as a range of new markets and products are in line with the expansion strategy. But t... read more…

Phosphagenics to Strengthen Skincare Partnership with Prestige Cosmetics Brand Le Métier de Beauté

12th June - Australian drug delivery technology company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), will continue its partnership for the use of its TPM® dermal delivery technology in Le Métier de Beauté (LMDB) skincare products after the sale of LMDB’s key assets in the United States. The sale to Maison de Beauté LLC was approved in late May after LMDB entered into a voluntary Chapter 11... read more…

Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer

3rd June - Spinifex Pharmaceuticals, a pain drug development company, today announces that it has appointed Dr Ronald Marcus as Chief Medical Officer. Dr Marcus will be responsible for driving the development of Spinifex’s lead candidate EMA401 and the Company’s pre-clinical pipeline. He takes up his position immediately.  EMA401 is a novel angiotensin II type 2 (AT2) receptor antagonist being ... read more…

Circadian’s VEGF-C Antibody, VGX-100, Shown to Be Well Tolerated in Phase Ia/b Clinical Trial

2nd June - Circadian Technologies (ASX: CIR, OTCQX: CKDXY), through its 100% owned subsidiary Ceres Oncology Pty Ltd, is pleased to announce that Phase 1 safety and clinical activity data demonstrating an encouraging clinical profile for VGX-100 in patients with advanced solid tumors was presented over the weekend at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in... read more…

New cancer detecting reagent available to US market, following FDA registration

29th May - Sienna has registered its lead product, Anti-hTERT antibody (SCD-A7), with the US Food and Drug Administration (FDA) Using SCD-A7, US-based pathology laboratories will soon develop new urine tests, with initialapplications expected in bladder cancer detection Advanced discussions underway with major US pathology laboratories, with first sales predicted in2014 Sienna Cancer D... read more…

Phosphagenics’ Topical Oxycodone Patch Alleviates Pain in Racehorses

21st May - • Rapid and effective relief for all racehorses in study• Positive implications for upcoming Phase 2 TPM®/Oxycodone trial A Phosphagenics Limited (ASX:POH, OTCQX: PPGNY) study using its TPM®/Oxycodone topical patch to manage shin soreness pain for thoroughbred racehorses found recovery from pain in all horses within 1-2 days. The study was conducted on six thoroughbreds, between tw... read more…

Circadian Appoints CFO and Company Secretary

21st May - Circadian Technologies Limited (ASX:CIR) is pleased to announce the appointment of Mr Michael Tonroe to the position of Chief Financial Officer and Company Secretary, effective May 19 2014. Mr Tonroe joins Circadian with over 20 years experience in finance and company secretarial roles. His most recent role was as Chief Financial Officer of the Australian Synchrotron Company Limited... read more…

Dimerix expands its Board and Scientific Advisory team

12th May - Dimerix Bioscience Pty Ltd is pleased to announce that Mr David Franklyn has joined the Board asa non-executive director and Dr Brian Richardson has joined our Scientific Advisory team. Mr Franklyn has extensive experience in the fields of financial analysis, corporate advice, business management and investor relations. He is also an experienced director of ASX listed companies acro... read more…

Nominations for Victoria Prize and Victoria Fellowships now open

29th April - Nominations for Victoria Prize and Victoria Fellowships now open Two $50,000 prizes for science and innovation Recognising Victoria’s established leaders in this field Victorian Coalition Government supporting established and emerging researchers Applications for two prestigious science and innovation programs, the 2014 Victoria Prize for Science & Innovation and the 2014... read more…

BioMelbourne Network - CEO Announcement

24th April - Today is a milestone for the BioMelbourne Network as we embrace change and announce Michelle Gallaher’s decision to leave the CEO role in July, 2014 and embark as a start-up entrepreneur in her own business. In July, Michelle will have been with the Network for six years and during that time has left an indelible mark on our sector with her enthusiasm, drive and passion. She has l... read more…

New CEO to implement growth plan at Cell Therapies Pty Ltd

21st April - Cell Therapies Pty Ltd (Cell Therapies), the leading manufacturer and distributor of cellular therapies in Asia Pacific, has appointed Dr Tim Oldham as CEO to implement an aggressive growth plan. Dr Oldham succeeds founding CEO and Managing Director Ray Wood who will continue as a Director. Cell Therapies has more than eleven years experience with a wide range of cellular therapie... read more…